SCHEMBL6132733

SCHEMBL6132733

COCCCCCCCCOC1CCC(N2CCN(c3ccc(C(=O)NN)cc3)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
ALOX15 P16050 1/20 0.43
HRH3 Q9Y5N1 1/20 0.40
KDM4E B2RXH2 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HDAC3 O15379 5/20 0.39
HDAC8 Q9BY41 5/20 0.39
SMYD3 Q9H7B4 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MBTD1 Q05BQ5 1/20 0.37
TP53BP1 Q12888 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132535 1.00 MEN1 (0.45) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6132370 0.89 SMYD3 (0.43) KMT2AKDM4EALDH1A1HDAC3HDAC8
SCHEMBL6132500 0.89 SMYD3 (0.43) KMT2AKDM4EALDH1A1HDAC3HDAC8
SCHEMBL6134735 0.89 SMYD3 (0.43) KMT2AKDM4EALDH1A1HDAC3HDAC8
SCHEMBL6132214 0.89 MEN1 (0.43) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6132429 0.89 MEN1 (0.43) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6132357 0.89 MEN1 (0.43) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6134505 0.87 GPR119 (0.41) MEN1KMT2AALOX15KDM4EALDH1A1
SCHEMBL6132432 0.87 ALDH1A1 (0.47) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6132359 0.87 ALDH1A1 (0.47) MEN1KMT2AITGB3ITGA2BALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 MEN1 1517/4885KMT2A 4695/4885ITGB3 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.